Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Arvinas, Inc. - Common Stock (NQ:ARVN)

10.70 +0.13 (+1.23%)
Streaming Delayed Price Updated: 10:58 AM EST, Nov 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,203,991
Open 10.61
Bid (Size) 10.70 (400)
Ask (Size) 10.72 (900)
Prev. Close 10.57
Today's Range 10.42 - 10.76
52wk Range 5.900 - 27.00
Shares Outstanding 70,800,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Arvinas Inc (NASDAQ:ARVN) Tops Q3 2025 Earnings Estimates and Provides Pipeline Updates ↗
Arvinas (ARVN) beat Q3 2025 earnings estimates, with revenue of $41.9M and a smaller-than-expected loss. The biotech also reported strong pipeline progress and a cash runway into 2028. 
Via Chartmill
News headline image
Arvinas Reports Third Quarter 2025 Financial Results and Provides Corporate Update
From Arvinas Inc.
Via GlobeNewswire

Performance

YTD
-43.4%
-43.4%
1 Month
+12.4%
+12.4%
3 Month
+49.2%
+49.2%
6 Month
+63.9%
+63.9%
1 Year
-53.9%
-53.9%

More News

Read More
News headline image
Earnings Scheduled For November 5, 2025 ↗
Via Benzinga
News headline image
Arvinas to Present Preclinical Data for ARV-393 at the 2025 American Society of Hematology (ASH) Annual Meeting
From Arvinas Inc.
Via GlobeNewswire
News headline image
What 4 Analyst Ratings Have To Say About Arvinas ↗
Via Benzinga
Wall Street Has Mixed Opinions On Future Of Arvinas’ Investigational Drug: Retail’s Got A Cautious Approach ↗
Via Stocktwits
News headline image
Earnings Scheduled For August 6, 2025 ↗
Via Benzinga
News headline image
Arvinas to Participate in Upcoming Investor Conferences
From Arvinas Inc.
Via GlobeNewswire
News headline image
Arvinas to Report Third Quarter 2025 Financial Results on November 5, 2025
From Arvinas Inc.
Via GlobeNewswire
News headline image
Arvinas Presents Preclinical Data for ARV-806 Demonstrating Robust and Differentiated Activity in Models of KRAS G12D-mutated Cancer at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
From Arvinas Inc.
Via GlobeNewswire
News headline image
Arvinas to Present Preclinical Data for ARV-806, a PROTAC KRAS G12D Degrader, at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
From Arvinas Inc.
Via GlobeNewswire
News headline image
Patient-Reported Outcomes from VERITAC-2 Clinical Trial Support Clinical Benefit of Vepdegestrant in Patients with ESR1-Mutated, ER+/HER2- Advanced or Metastatic Breast Cancer Previously Treated with Endocrine-Based Therapy
From Arvinas Inc.
Via GlobeNewswire
News headline image
Forecasting The Future: 7 Analyst Projections For Arvinas ↗
Via Benzinga
News headline image
This GE Vernova Analyst Turns Bearish; Here Are Top 5 Downgrades For Wednesday ↗
Via Benzinga
News headline image
Karooooo Posts Downbeat Earnings, Joins ASP Isotopes And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗
Via Benzinga
News headline image
Arvinas to Present Data from the Vepdegestrant Clinical Development Program at the 2025 European Society for Medical Oncology (ESMO) Congress
From Arvinas Inc.
Via GlobeNewswire
News headline image
Arvinas Presents Late Breaking, Positive Phase 1 Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson’s Disease and Movement Disorders®
From Arvinas Inc.
Via GlobeNewswire
News headline image
Arvinas to Present Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson’s Disease and Movement Disorders®
From Arvinas Inc.
Via GlobeNewswire
News headline image
Arvinas Provides Update on Collaboration with Pfizer and Announces Further Actions to Support Value Creation
From Arvinas Inc.
Via GlobeNewswire
News headline image
Arvinas to Participate in Upcoming Investor Conferences
From Arvinas Inc.
Via GlobeNewswire
News headline image
Arvinas Announces FDA Acceptance of the New Drug Application for Vepdegestrant for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer
From Arvinas Inc.
Via GlobeNewswire
News headline image
Arvinas Inc (NASDAQ:ARVN) Reports Q2 2025 Earnings: Revenue Misses but EPS Beats Estimates ↗
Via Chartmill
News headline image
Arvinas Reports Second Quarter 2025 Financial Results and Provides Corporate Update
From Arvinas Inc.
Via GlobeNewswire
News headline image
Arvinas to Report Second Quarter 2025 Financial Results on August 6, 2025
From Arvinas Inc.
Via GlobeNewswire
News headline image
Arvinas Announces Retirement of Chief Executive Officer and Succession Plan
From Arvinas Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Arvinas, Inc. - Common Stock publicly traded?
Yes, Arvinas, Inc. - Common Stock is publicly traded.
What exchange does Arvinas, Inc. - Common Stock trade on?
Arvinas, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Arvinas, Inc. - Common Stock?
The ticker symbol for Arvinas, Inc. - Common Stock is ARVN on the Nasdaq Stock Market
What is the current price of Arvinas, Inc. - Common Stock?
The current price of Arvinas, Inc. - Common Stock is 10.70
When was Arvinas, Inc. - Common Stock last traded?
The last trade of Arvinas, Inc. - Common Stock was at 11/17/25 10:58 AM ET
What is the market capitalization of Arvinas, Inc. - Common Stock?
The market capitalization of Arvinas, Inc. - Common Stock is 757.56M
How many shares of Arvinas, Inc. - Common Stock are outstanding?
Arvinas, Inc. - Common Stock has 758M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.